Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais; Adiogo Dieudonné

doi:doi:10.11648/j.ijde.20210604.12

Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, Adiogo Dieudonné

Published in International Journal of Diabetes and Endocrinology (Volume 6, Issue 4)

Received: 17 August 2021 Accepted: 16 October 2021 Published: 28 October 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: C-peptide is the best indicator of endogenous insulin secretion; it makes it possible to optimize the treatment, and to prevent the occurrence and the evolution of the damages resulting from type 2 diabetes. The present study reports the variation of C-peptide levels according to the types of treatment administrated and the high blood pressure in type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. Methodology Over a period of 9 months (from October, 1^st 2017 to June, 30^th 2018), we conducted an analytical cross-sectional study involving subjects with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. Inclusion criteria we included any subject whose diagnosis of type 2 diabetes was mentioned in the medical file. The fasting C-peptide assays were performed according to the principle of electrochemiluminescence. The ANOVA and PEARSON tests were use to investigate on the one hand the correlations between the C peptide levels and the types of treatment administered, and on the other hand between the C-peptide levels and arterial hypertension. The significant threshold was set at P <0.05. Results: Our population, made up of 90 subjects, had a mean age of 58±12.31 years, sex ratio 0.8 in favor of women. The mean duration of diabetes was 8.71±6, 94 years, we had 30 hypertensive subjects under hypertensive treatment, the mean C-peptide levels was 2.50±1.68ng / ml. We found that C-peptide levels increased with patient ages (P=0.004), a significant correlation between C-peptide levels and high blood pressure (P=0.022), and C-Peptide levels varied significantly depending on the type of treatment (P=0.04). Conclusion: Type 2 diabetic patients on oral antidiabetic drugs, and having a low level of C-peptide, should undergo a modification of their treatment by the addition (or the replacement) of insulin, for better glycemic control. Diabetic and hypertensive patients are more exposed to micro and macrovascular complications. Hence the importance of instituting more assiduous blood pressure control, appropriate hypotensive therapy, as well as training patients in self-management and prevention of the onset of complications related to diabetes.

Published in	International Journal of Diabetes and Endocrinology (Volume 6, Issue 4)
DOI	10.11648/j.ijde.20210604.12
Page(s)	131-133
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

C-peptide, Type 2 Diabetes, Hypertension, Douala

References

[1]	Sauvanet J. P, Sheen A. J, Ziegler O., Drouin P., «insulino sensibilité, surcharge pondérale et diabète de type 2» Diabetes Metab, 2001, 27, cahier 2, 189-293.
[2]	Léonel Soyeux et al. «effet of immigration in France on type 2 diabetes mellitus risk» 8 december 2003, p31.
[3]	Konstantinos Papatheodoru, Maciej Bnach, Eleni Bekiari, Manfredi Rizzo, Michael Edmons. Complications of Diabetes 2017. Journal of Diabetes Research March 2018; volume 2018.
[4]	Marian Sue Kirkman, Hussain Mahmud, Mary T. Korytkowski. Intensive Blood Glucose Control and Vascular Outhcomes in Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism clinics 47 (1), 81-96, 2018.
[5]	Xuanqian Xie, Hindrik Vondeling. Cost-utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, PR China. Value in Health 11, S23-S32, 2008.
[6]	Emma Leighton, Christopher AR Sainsbury, Gregory C. Jones. A practical Reviiew of C-peptide Testing in Diabetes. Diabetes therapy 8 (3), 475-487, 2017.
[7]	Beliakin SA, Serebrennikov VN, Shklovskii BL, Patsenko MB. C-peptide as an early diagnostic of metabolic syndrome and indicator of cardiovascular disease in patients with type 2 diabetes mellitus. Voen Med Zh 2014; 335 (10): 46-9.
[8]	AG Jones, AT Hattersley. Diabetic medicine 30 (7), 803-817, 2013.
[9]	www.roche.com: notice C-peptide Elecsys 2013-11, V 9.0 English.
[10]	Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 2005; 97: 1113–1118.
[11]	Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. ExpClinEndocrinol Diabetes 1999; 107: 40–45.
[12]	Mbanya JC, Sobngwi E. Diabetes, microvascular and macrovascular disease in Africa. Journal of Cardiovascular Risk. 2003; 97 102.
[13]	Khadija Diyane, Nawal El Ansari, Ghizlane El Mghari, Karim Anzid, Mohamed Cherkaoui. Caractéristiques de l’association diabète type 2 et hypertension artérielle chez le sujet âgé de 65 ans et plus. Pan African Medical Journal March 2013.
[14]	Ben-Hamouda-Chihaoui Melika, Kanoun Faouzi, Ftouhi Bouchra, et al. Évaluation de l’équilibre tensionnel par lamesure ambulatoire de la pression artérielle et étude desfacteurs associés à un mauvais contrôle tensionnel chez 300 diabétiques de type 2 hypertendus traités. Ann Cardiol Angeiol. 2011; 60 (2): 71-76. PubMed\| Google Scholar.
[15]	Katchunga Philippe, Hermans Michel, et al. Hypertension artérielle, insulinorésistance et maladie rénale chronique dans un groupe de diabétiques de type 2 du Sud-Kivu, RD Congo. Néphrologie et thérapeutique. 2010; 6 (6): 520-525. PubMed Google Scholar.
[16]	Mason Martin, Freemantle North, Gibson Martin, et al. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care. 2005; 28 (1): 40-6.
[17]	B Berger, Stenstrom, G Sundkvist. Random C-peptide in the Classification of Diabetes. Scandinavian Journal of Clinical and Laboratory Investigation 60 (8), 687-693, 2000.
[18]	Johnny Ludvigsson, Annelie Carlsson, Gun Forsander, Sten Ivarsson, I. Kkockum, Ake. C-peptide in the Classification of Diabtes in Children and Adelescents. Pediatric Diabetes 13 (1), 45-50, 2012.

Cite This Article

Plain Text BibTeX RIS

APA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. (2021). Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. International Journal of Diabetes and Endocrinology, 6(4), 131-133. https://doi.org/10.11648/j.ijde.20210604.12

Copy | Download

ACS Style

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. Int. J. Diabetes Endocrinol. 2021, 6(4), 131-133. doi: 10.11648/j.ijde.20210604.12

Copy | Download

AMA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. Int J Diabetes Endocrinol. 2021;6(4):131-133. doi: 10.11648/j.ijde.20210604.12

Copy | Download

@article{10.11648/j.ijde.20210604.12,
  author = {Manta Diane and Mbango-Ekouta Noel Désirée and Nda Mefo'o Jean Pierre and Assiene Oyong Damase Serge and Eloumou Bagnaka Servais and Adiogo Dieudonné},
  title = {Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {6},
  number = {4},
  pages = {131-133},
  doi = {10.11648/j.ijde.20210604.12},
  url = {https://doi.org/10.11648/j.ijde.20210604.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20210604.12},
  abstract = {Introduction: C-peptide is the best indicator of endogenous insulin secretion; it makes it possible to optimize the treatment, and to prevent the occurrence and the evolution of the damages resulting from type 2 diabetes. The present study reports the variation of C-peptide levels according to the types of treatment administrated and the high blood pressure in type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. Methodology Over a period of 9 months (from October, 1st 2017 to June, 30th 2018), we conducted an analytical cross-sectional study involving subjects with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. Inclusion criteria we included any subject whose diagnosis of type 2 diabetes was mentioned in the medical file. The fasting C-peptide assays were performed according to the principle of electrochemiluminescence. The ANOVA and PEARSON tests were use to investigate on the one hand the correlations between the C peptide levels and the types of treatment administered, and on the other hand between the C-peptide levels and arterial hypertension. The significant threshold was set at P Results: Our population, made up of 90 subjects, had a mean age of 58±12.31 years, sex ratio 0.8 in favor of women. The mean duration of diabetes was 8.71±6, 94 years, we had 30 hypertensive subjects under hypertensive treatment, the mean C-peptide levels was 2.50±1.68ng / ml. We found that C-peptide levels increased with patient ages (P=0.004), a significant correlation between C-peptide levels and high blood pressure (P=0.022), and C-Peptide levels varied significantly depending on the type of treatment (P=0.04). Conclusion: Type 2 diabetic patients on oral antidiabetic drugs, and having a low level of C-peptide, should undergo a modification of their treatment by the addition (or the replacement) of insulin, for better glycemic control. Diabetic and hypertensive patients are more exposed to micro and macrovascular complications. Hence the importance of instituting more assiduous blood pressure control, appropriate hypotensive therapy, as well as training patients in self-management and prevention of the onset of complications related to diabetes.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered
AU  - Manta Diane
AU  - Mbango-Ekouta Noel Désirée
AU  - Nda Mefo'o Jean Pierre
AU  - Assiene Oyong Damase Serge
AU  - Eloumou Bagnaka Servais
AU  - Adiogo Dieudonné
Y1  - 2021/10/28
PY  - 2021
N1  - https://doi.org/10.11648/j.ijde.20210604.12
DO  - 10.11648/j.ijde.20210604.12
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 131
EP  - 133
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20210604.12
AB  - Introduction: C-peptide is the best indicator of endogenous insulin secretion; it makes it possible to optimize the treatment, and to prevent the occurrence and the evolution of the damages resulting from type 2 diabetes. The present study reports the variation of C-peptide levels according to the types of treatment administrated and the high blood pressure in type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. Methodology Over a period of 9 months (from October, 1st 2017 to June, 30th 2018), we conducted an analytical cross-sectional study involving subjects with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. Inclusion criteria we included any subject whose diagnosis of type 2 diabetes was mentioned in the medical file. The fasting C-peptide assays were performed according to the principle of electrochemiluminescence. The ANOVA and PEARSON tests were use to investigate on the one hand the correlations between the C peptide levels and the types of treatment administered, and on the other hand between the C-peptide levels and arterial hypertension. The significant threshold was set at P Results: Our population, made up of 90 subjects, had a mean age of 58±12.31 years, sex ratio 0.8 in favor of women. The mean duration of diabetes was 8.71±6, 94 years, we had 30 hypertensive subjects under hypertensive treatment, the mean C-peptide levels was 2.50±1.68ng / ml. We found that C-peptide levels increased with patient ages (P=0.004), a significant correlation between C-peptide levels and high blood pressure (P=0.022), and C-Peptide levels varied significantly depending on the type of treatment (P=0.04). Conclusion: Type 2 diabetic patients on oral antidiabetic drugs, and having a low level of C-peptide, should undergo a modification of their treatment by the addition (or the replacement) of insulin, for better glycemic control. Diabetic and hypertensive patients are more exposed to micro and macrovascular complications. Hence the importance of instituting more assiduous blood pressure control, appropriate hypotensive therapy, as well as training patients in self-management and prevention of the onset of complications related to diabetes.
VL  - 6
IS  - 4
ER  -

Copy | Download

Author Information

Manta Diane

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Mbango-Ekouta Noel Désirée

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Nda Mefo'o Jean Pierre

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Assiene Oyong Damase Serge

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Eloumou Bagnaka Servais

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Adiogo Dieudonné

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. (2021). Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. International Journal of Diabetes and Endocrinology, 6(4), 131-133. https://doi.org/10.11648/j.ijde.20210604.12

Copy | Download

ACS Style

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. Int. J. Diabetes Endocrinol. 2021, 6(4), 131-133. doi: 10.11648/j.ijde.20210604.12

Copy | Download

AMA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered. Int J Diabetes Endocrinol. 2021;6(4):131-133. doi: 10.11648/j.ijde.20210604.12

Copy | Download

@article{10.11648/j.ijde.20210604.12,
  author = {Manta Diane and Mbango-Ekouta Noel Désirée and Nda Mefo'o Jean Pierre and Assiene Oyong Damase Serge and Eloumou Bagnaka Servais and Adiogo Dieudonné},
  title = {Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {6},
  number = {4},
  pages = {131-133},
  doi = {10.11648/j.ijde.20210604.12},
  url = {https://doi.org/10.11648/j.ijde.20210604.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20210604.12},
  abstract = {Introduction: C-peptide is the best indicator of endogenous insulin secretion; it makes it possible to optimize the treatment, and to prevent the occurrence and the evolution of the damages resulting from type 2 diabetes. The present study reports the variation of C-peptide levels according to the types of treatment administrated and the high blood pressure in type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. Methodology Over a period of 9 months (from October, 1st 2017 to June, 30th 2018), we conducted an analytical cross-sectional study involving subjects with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. Inclusion criteria we included any subject whose diagnosis of type 2 diabetes was mentioned in the medical file. The fasting C-peptide assays were performed according to the principle of electrochemiluminescence. The ANOVA and PEARSON tests were use to investigate on the one hand the correlations between the C peptide levels and the types of treatment administered, and on the other hand between the C-peptide levels and arterial hypertension. The significant threshold was set at P Results: Our population, made up of 90 subjects, had a mean age of 58±12.31 years, sex ratio 0.8 in favor of women. The mean duration of diabetes was 8.71±6, 94 years, we had 30 hypertensive subjects under hypertensive treatment, the mean C-peptide levels was 2.50±1.68ng / ml. We found that C-peptide levels increased with patient ages (P=0.004), a significant correlation between C-peptide levels and high blood pressure (P=0.022), and C-Peptide levels varied significantly depending on the type of treatment (P=0.04). Conclusion: Type 2 diabetic patients on oral antidiabetic drugs, and having a low level of C-peptide, should undergo a modification of their treatment by the addition (or the replacement) of insulin, for better glycemic control. Diabetic and hypertensive patients are more exposed to micro and macrovascular complications. Hence the importance of instituting more assiduous blood pressure control, appropriate hypotensive therapy, as well as training patients in self-management and prevention of the onset of complications related to diabetes.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of C-peptide in Type 2 Diabetic Patients in Douala Cameroon: C-peptide Correlation with Arterial Hypertension and the Types of Treatment Administered
AU  - Manta Diane
AU  - Mbango-Ekouta Noel Désirée
AU  - Nda Mefo'o Jean Pierre
AU  - Assiene Oyong Damase Serge
AU  - Eloumou Bagnaka Servais
AU  - Adiogo Dieudonné
Y1  - 2021/10/28
PY  - 2021
N1  - https://doi.org/10.11648/j.ijde.20210604.12
DO  - 10.11648/j.ijde.20210604.12
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 131
EP  - 133
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20210604.12
AB  - Introduction: C-peptide is the best indicator of endogenous insulin secretion; it makes it possible to optimize the treatment, and to prevent the occurrence and the evolution of the damages resulting from type 2 diabetes. The present study reports the variation of C-peptide levels according to the types of treatment administrated and the high blood pressure in type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. Methodology Over a period of 9 months (from October, 1st 2017 to June, 30th 2018), we conducted an analytical cross-sectional study involving subjects with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. Inclusion criteria we included any subject whose diagnosis of type 2 diabetes was mentioned in the medical file. The fasting C-peptide assays were performed according to the principle of electrochemiluminescence. The ANOVA and PEARSON tests were use to investigate on the one hand the correlations between the C peptide levels and the types of treatment administered, and on the other hand between the C-peptide levels and arterial hypertension. The significant threshold was set at P Results: Our population, made up of 90 subjects, had a mean age of 58±12.31 years, sex ratio 0.8 in favor of women. The mean duration of diabetes was 8.71±6, 94 years, we had 30 hypertensive subjects under hypertensive treatment, the mean C-peptide levels was 2.50±1.68ng / ml. We found that C-peptide levels increased with patient ages (P=0.004), a significant correlation between C-peptide levels and high blood pressure (P=0.022), and C-Peptide levels varied significantly depending on the type of treatment (P=0.04). Conclusion: Type 2 diabetic patients on oral antidiabetic drugs, and having a low level of C-peptide, should undergo a modification of their treatment by the addition (or the replacement) of insulin, for better glycemic control. Diabetic and hypertensive patients are more exposed to micro and macrovascular complications. Hence the importance of instituting more assiduous blood pressure control, appropriate hypotensive therapy, as well as training patients in self-management and prevention of the onset of complications related to diabetes.
VL  - 6
IS  - 4
ER  -

Copy | Download